Cytokinetics Inc (NASDAQ: CYTK) kicked off on Friday, down -3.29% from the previous trading day, before settling in for the closing price of $55.93. Over the past 52 weeks, CYTK has traded in a range of $25.98-$110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.30% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 6.02%. With a float of $113.74 million, this company’s outstanding shares have now reached $117.66 million.
In an organization with 423 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -2886.73%, operating margin of -16148.37%, and the pretax margin is -17398.82%.
Cytokinetics Inc (CYTK) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 3.33%, while institutional ownership is 113.93%. The most recent insider transaction that took place on Sep 03 ’24, was worth 420,973. In this transaction EVP Research & Development of this company sold 7,384 shares at a rate of $57.01, taking the stock ownership to the 122,920 shares. Before that another transaction happened on Sep 03 ’24, when Company’s President & CEO sold 5,000 for $57.03, making the entire transaction worth $285,150. This insider now owns 397,456 shares in total.
Cytokinetics Inc (CYTK) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.35 earnings per share (EPS), lower than consensus estimate (set at -0.74) by -0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2033.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.37, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -4.86 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.46 million. That was inferior than the volume of 2.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 32.79%. Additionally, its Average True Range was 2.23.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 32.30%, which indicates a significant increase from 16.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.41% in the past 14 days, which was lower than the 49.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.16, while its 200-day Moving Average is $61.77. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $55.90. Second resistance stands at $57.71. The third major resistance level sits at $59.05. If the price goes on to break the first support level at $52.74, it is likely to go to the next support level at $51.40. Assuming the price breaks the second support level, the third support level stands at $49.59.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 6.36 billion has total of 104,854K Shares Outstanding. Its annual sales at the moment are 7,530 K in contrast with the sum of -526,240 K annual income. Company’s last quarter sales were recorded 250 K and last quarter income was -143,320 K.
